Human Accell siRNA Library - Protein Kinase

Targeted gene silencing in difficult-to-transfect cells

An arrayed collection of siRNA reagents for RNAi screening, targeting human kinases. Accell siRNA permits RNAi screening in difficult-to-transfect cells with no transfection reagent, virus, or electroporation.

The Human Accell Protein Kinase siRNA Library includes siRNA reagents directed against phylogenetically related kinases. Protein kinases are key regulators of cell function and are known to direct the activity, localization, and function of many proteins. They are prominent in signal transduction and are crucial for the coordination of complex cellular functions such as cell cycle regulation, gene transcription, and apoptosis. The mutation or dysregulation of genes encoding protein kinases has been linked to many disease states, including diabetes, inflammatory disorders and cancer.

Accell siRNA achieves what no other RNAi product can claim: delivery into difficult-to-transfect cells without transfection reagents, virus, or electroporation. Researchers around the world are achieving targeted gene silencing in cells that had previously been beyond the reach of conventional RNAi products due to toxicity caused by transfection reagents or undesirable viral responses.


  • Accell siRNA enters cells without the need for transfection reagents, virus (or viral vectors), or instruments
  • Proven performance in neuronal, immunological, primary, and other difficult-to-transfect cell types
  • Extended-duration knockdown with optimized continuous application
  • Available as SMARTpool siRNA reagents or a Set of 4 siRNAs in 96 well plates

Gene Targets

For a complete list of target genes in this siRNA Library, please email Technical Support, or call 1-800-235-9880. International customers, please call 303-604-9499 or your local Sales Representative.

Experimental Considerations

  • Accell siRNA works at a higher concentration than conventional siRNA; recommended 1 µM working concentration
  • Delivery may be inhibited by the presence of BSA in serum. Optimization studies with serum-free media formulations (Accell Delivery Media) or < 2.5% serum in standard media is recommended
  • Full-serum media can be added back after 48 hours of incubation. Optimal mRNA silencing is typically achieved by 72 hours or up to 96 hours for protein knockdown
Shipping ConditionAmbient
Stability at Recommended Storage ConditionsAt least 12 months
Storage Condition-20 C
Cell types demonstrating effective silencing with Accell siRNA

Cell types demonstrating effective silencing with Accell siRNA

Cell types demonstrating effective silencing with Accell siRNA

Internal validation and peer-reviewed publications report numerous successes with difficult-to-transfect cell types. See the References tab for a list of publications.

The Accell siRNA application protocol simplifies targeted gene knockdown

The Accell siRNA application protocol simplifies targeted gene knockdown

The Accell siRNA application protocol simplifies targeted gene knockdown

(1) Combine Accell siRNA with Accell delivery media (or other low- or no-serum media). (2) Add Accell delivery mix directly to cells, and incubate for 72 hours.


  1. B.D. Parsons, A. Schindler, D.H. Evans, E. Foley, A direct phenotypic comparison of siRNA pools and multiple individual duplexes in a functional assay. PLoS One. 4(12), e8471 (2009).
  2. M. Jiang, R. Instrell, B. Saunders, H. Berven, M. Howell, Tales from an academic RNAi screening facility; FAQs. Brief Funct. Genomics. 10(4), 227-237 (2011). [doi: 10.1093/bfgp/elr016]


  1. Click to view a more comprehensive list of Accell siRNA citations.
  2. S. Suzuki et al., Differential Roles of Epac in Regulating Cell Death in Neuronal and Myocardial Cells. J. Biol. Chem. 285, 24248-24259 (July 2010). [primary mouse cortical neurons (E15-17)]
  3. U. Dreses-Werringloer et al., A Polymorphism in CALHM1 Influences Ca2+ Homeostasis, Ab Levels, and Alzheimer’s Disease Risk. Cell. 133, 1149-1161 (27 June 2008). [SHSY-5Y; human neuroblastoma]
  4. S. Byas et al., Human Embryonic Stem Cells Maintain Pluripotency after E-Cadherin Expression Knockdown. FASEB J. 24, lb172 (Apr 2010). [H9 stem cell lines]
  5. V. Saini et al., CXC Chemokine Receptor 4 Is a Cell Surface Receptor for Extracellular Ubiquitin. J. Biol. Chem.  285, 15566-15576 (May 2010). [THP-1 monocytes]
  6. D. Smirnov et al., Genetic Analysis of Radiation-induced Changes in Human Gene Expression. Nature. 459, 10.1038/nature07940 (28 May 2009). [immortalized B cells]